RxDoctor Payments Data

George Massoud, MD

Cardiovascular Disease · Alamogordo, NMNPI 1003800988

Payments from drug & device makers

$607in general payments, 2019–2025

Across 25 payments — averaging $24.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$151
  • C2n Diagnostics, LLC$118
  • Edwards Lifesciences$107
  • Boehringer Ingelheim$60
  • Regeneron Healthcare Solutions, Inc.$50
  • Philips North America LLC$33
  • plus $88 from 4 others

What the payments were for

  • Food & beverage$59498%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$607 in reported general payments places this provider in the 30th percentile of 101 cardiovascular disease providers in New Mexico.

See all cardiovascular disease providers in New Mexico

Medicare billing

Part B allowed, 2024
$203,704
Medicare patients
957
Services billed
4,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan179$178,396
EliquisApixaban177$171,163
JardianceEmpagliflozin159$76,019
FarxigaDapagliflozin Propanediol62$56,556
XareltoRivaroxaban13$19,080
Metoprolol Succinate292$4,544
Warfarin Sodium277$2,451
Atorvastatin Calcium151$2,076
Rosuvastatin Calcium119$1,954
Carvedilol214$1,739
Digoxin100$1,624
Potassium Chloride104$1,603
Amlodipine Besylate119$1,320
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$1,230
Spironolactone148$1,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$28$178,396179 claims
Boehringer IngelheimJardiance$60$76,019159 claims
Johnson & JohnsonXarelto$29$19,08013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 101 cardiovascular disease providers in New Mexico.

Other cardiovascular disease in Alamogordo

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →